Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I

Recommendation ID: DG32/1
Question: The committee recommended that further studies should be done in a HPV primary screening setting. These studies should incorporate clinical outcome data and be designed to minimise verification bias. Future studies should consider measuring variability and should also take into account HPV genotyping status when possible, so that the difference in accuracy in a population vaccinated against HPV types 16 and 18 can be better understood.
Any explanatory notes (if applicable): The committee noted that human papilloma virus (HPV) primary screening is being implemented across England (see section 5.2) and that the base-case economic modelling for HPV primary screening in this assessment was based on preliminary data only (see section 5.13).

Source guidance details

Comes from guidance: Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I
Number: DG32
Date issued: April 2018

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	30/04/2018